Newsletter
Before the first call of the day.
Every morning at 7am ET, we send the day's nine most-important filings, deals, and enforcement actions. Written for people who read the primary sources anyway.
hello@the483.com · Early access · Free · No sponsor copy
№ 113
Nine observations you didn't want to receive this morning.
Lilly Bought Engage Bio's DNA Platform for $202M
Eli Lilly paid up to $202M for a preclinical biotech with zero disclosed programs: the platform bet driving its $21B 2026 buying spree.
Also on the docket
Apple Stopped $2.2B in App Store Fraud in 2025
Apple stopped $2.2B in App Store fraud in 2025, rejected 1.1 billion fake account creations, and now sits at $11.2B blocked over six years.
Fined $1M, Yotta Customers Still Out Millions
California's first-ever Yotta penalty is $1M, but the 18,000 California customers still waiting for Synapse restitution call it a rounding error.
Bimzelx Beats Skyrizi 49% to 38% on ACR50 in PsA Trial
BE BOLD's Phase 3 data put a 10-point ACR50 gap between Bimzelx and Skyrizi, the $17.56B drug AbbVie built its post-Humira franchise on.
● What you get
The brief
Nine filings, ranked. FDA letters, SEC orders, deals, docket updates. The dollar figure lives in the first sentence.
● What you won't get
No slop
No sponsored links masquerading as analysis. No market predictions. No "here are five trends to watch." Just the filings.
● Who reads us
People with standing
Compliance officers, GCs, deal lawyers, buy-side analysts. People who already read primary documents and want the context filled in fast.